康日百奥生物科技（苏州）有限公司
100-499人
公司优势
Bioworkshops Suzhou, a biopharmaceutical company headquartered in Hong Kong, collaborates with international partners to develop pioneering and superior antibody products for China and the global market. We specialize in creating clinical drug substances and products using cell culture methods, adhering to international standards. Our mission is to expedite the development and approval of biological products faster than any other Chinese competitor through the strategic application of manufacturing science.
Recently, the company has acquired a 28,000 square-meter facility in Suzhou and invested over RMB300 million in constructing state-of-the-art development and clinical manufacturing facilities in 2019. This investment positions us well to aim for the first IND approval in 2020.
Our team is comprised of talented and productive professionals, led by experienced founders from Australia and China who have a track record of launching and guiding biologics development and manufacturing organizations worldwide for over two decades. In the last five years alone, they've successfully launched more than ten new antibody products for the US, Australian, and Chinese markets, and completed the design, construction, and startup of four biologics development and manufacturing centers:
- Clinical and commercial production facilities
- Inspected for compliance with US-FDA, NMPA, TFDA, and TGA regulations for filing CTAs/INDs and commercial products
We've swiftly assembled a startup team and are actively recruiting additional experts to grow our workforce to over 150 employees within the next year.
Quality management is a critical component of our operations, requiring a deliberate approach with a commitment to continuous improvement. Bioworkshops' Quality Management System covers all aspects of our business, with a special emphasis on ensuring pharmaceutical product quality during development and manufacturing processes to meet Chinese, European, and American Good Manufacturing Practice (GMP) standards.
Our facility is situated in the heart of Suzhou Industrial Park, where we are constructing high-capacity drug discovery, development, and manufacturing facilities that include:
- Development capacity for up to 8-12 IND applications annually
- Clinical drug substance manufacturing to 2,000L scale
- Aseptic filling of liquid products into vials
- Best-in-class bioprocesses and analytical capabilities
At Bioworkshops, our founding values emphasize a strong culture and shared purpose, focusing on:
- Innovation and excellence in biologics development
- Trust-based relationships grounded in honesty
- Sustainability measured by workplace safety, environmental impact, and long-term business success
- Enthusiasm for ambitious goals and creative problem-solving
- Respect for the persistent effort required to achieve ambitious goals in our industry
Recently, the company has acquired a 28,000 square-meter facility in Suzhou and invested over RMB300 million in constructing state-of-the-art development and clinical manufacturing facilities in 2019. This investment positions us well to aim for the first IND approval in 2020.
Our team is comprised of talented and productive professionals, led by experienced founders from Australia and China who have a track record of launching and guiding biologics development and manufacturing organizations worldwide for over two decades. In the last five years alone, they've successfully launched more than ten new antibody products for the US, Australian, and Chinese markets, and completed the design, construction, and startup of four biologics development and manufacturing centers:
- Clinical and commercial production facilities
- Inspected for compliance with US-FDA, NMPA, TFDA, and TGA regulations for filing CTAs/INDs and commercial products
We've swiftly assembled a startup team and are actively recruiting additional experts to grow our workforce to over 150 employees within the next year.
Quality management is a critical component of our operations, requiring a deliberate approach with a commitment to continuous improvement. Bioworkshops' Quality Management System covers all aspects of our business, with a special emphasis on ensuring pharmaceutical product quality during development and manufacturing processes to meet Chinese, European, and American Good Manufacturing Practice (GMP) standards.
Our facility is situated in the heart of Suzhou Industrial Park, where we are constructing high-capacity drug discovery, development, and manufacturing facilities that include:
- Development capacity for up to 8-12 IND applications annually
- Clinical drug substance manufacturing to 2,000L scale
- Aseptic filling of liquid products into vials
- Best-in-class bioprocesses and analytical capabilities
At Bioworkshops, our founding values emphasize a strong culture and shared purpose, focusing on:
- Innovation and excellence in biologics development
- Trust-based relationships grounded in honesty
- Sustainability measured by workplace safety, environmental impact, and long-term business success
- Enthusiasm for ambitious goals and creative problem-solving
- Respect for the persistent effort required to achieve ambitious goals in our industry
热招职位
相关职位
热门城市
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
嘉兴唯实科技有限公司，成立于2022年7月18日，位于浙江省嘉兴市南湖区大桥镇亚太路906号D2号楼301-1室，主要从事应用软件开发业务。公司员工规模为1-49人。
上海创兴辛汽车服务有限公司，公司规模为少于50人，公司类型为民营公司，所属行业为餐饮业。
广州胡仅劳务有限公司，公司规模为少于50人，公司类型为民营公司，所属行业为计算机软件。
中航国际钢铁贸易有限公司（简称：中航国际钢贸）是航空工业集团的三级单位，中航科创有限公司的控股子公司，于1999年成立，2010年底完成增资扩股更名，注册资本金为9800万元。
中航国际钢贸的商业模式以供应链管理为核心，为钢厂在采购、销售、物流、环保改造、技术升级和信息化等方面提供全面的供应链管理服务，目前合作的钢厂产能资源超过千万吨。
自2013年起，中航国际钢贸连续入选宁波市百强企业，并名列前茅。从2014年开始，持续入围浙江省百强企业名单。2020年，公司荣获宁波市服务业百强企业及综合百强企业称号，2021年的年销售收入突破400亿元。
贵阳鼎山新能源有限公司专注于新能源领域，从事磷酸铁锂电池的研发、生产、制造和销售，是一家综合型新能源企业。公司产品类型包括储能电池、动力电池、铅酸替换、换电项目及民用市场等，致力于成为客户最乐意合作的电源系统综合供应商。